Fosamax and Osteonecrosis of the Jaw: Examining the Scientific Evidence
Latest update (2026-05)
FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]
From General Health Communication to Targeted Drug Safety
The legacy of general health and science communication has long served to inform public understanding of medical conditions and therapeutic interventions. Within this tradition, the dissemination of balanced, evidence-based information has been paramount, particularly regarding the benefits and risks associated with pharmaceutical treatments. This foundational approach has enabled audiences to navigate complex health landscapes, from chronic disease management to preventive care. As this informational heritage evolves, it increasingly intersects with specialized areas of clinical concern, where the focus shifts from broad population health to specific, adverse outcomes linked to particular drug exposures. One such area of growing attention involves the relationship between bisphosphonate therapy, commonly prescribed for bone density disorders, and the development of osteonecrosis of the jaw (ONJ). This condition, characterized by exposed necrotic bone in the maxillofacial region, has prompted rigorous scientific inquiry into its causation. The pivot from general health education to this focused inquiry necessitates a careful examination of exposure parameters, particularly in contexts where prolonged or high-dose administration may elevate risk. Understanding the transition from routine therapeutic use to the identification of a potential clinical hazard requires a neutral assessment of the evidence base, without premature mechanistic attribution. This transition thus reframes the legacy of health communication toward a more targeted evaluation of drug-safety profiles in vulnerable populations.
Fosamax: Mechanism and Approved Uses
Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves increasing bone mass and reducing fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a serious adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation involves bone exposure in the oral cavity, often accompanied by pain, swelling, and infection. Diagnosis relies on clinical examination and imaging, with a focus on identifying necrotic bone that persists for more than eight weeks in the absence of radiation therapy to the jaw. The condition has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
Mechanistic Pathways and Risk Factors
The mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but research provides insights. Bisphosphonates like alendronate inhibit osteoclast activity, reducing bone turnover. In the jawbone, which undergoes high remodeling due to dental function and infection, this suppression may impair healing after dental procedures. Multiscale characterization of jawbone in estrogen-deficient rats treated with bisphosphonate (alendronate) shows effects on jawbone properties, including static and dynamic mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077/). This suggests that bisphosphonate treatment alters jawbone structure and function, potentially predisposing it to necrosis. Additionally, known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw. It states that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and that it is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also notes that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label does not provide specific guidance on the optimal duration of use, noting that the optimal duration has not been determined and that for low-risk patients, discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This leaves some ambiguity for clinicians and patients regarding long-term risk. In summary, scientific evidence connects Fosamax to ONJ through clinical reports, mechanistic studies, and risk factor analysis. The prescribing information includes warnings, but the rarity of ONJ and the need for additional risk factors complicate causation assessments. Patients and clinicians should weigh the benefits of Fosamax for osteoporosis against the potential risk of ONJ, particularly in those with dental risk factors or prolonged use.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is Fosamax and how does it work?
Fosamax (alendronate sodium) is a bisphosphonate medication used to treat and prevent osteoporosis in postmenopausal women, increase bone mass in men with osteoporosis, treat glucocorticoid-induced osteoporosis, and treat Paget's disease of bone. It works by inhibiting osteoclast activity, thereby reducing bone turnover and increasing bone mass, which helps prevent fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
What is osteonecrosis of the jaw (ONJ) and how is it linked to Fosamax?
Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, often associated with tooth extraction or local infection. It has been reported in patients taking bisphosphonates, including Fosamax. The link is supported by clinical reports, mechanistic studies showing altered jawbone properties, and a temporal relationship where symptoms may appear days to months after starting the drug and often improve upon discontinuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56) (https://pubmed.ncbi.nlm.nih.gov/40345077/).
What are the risk factors for developing ONJ while taking Fosamax?
Risk factors for ONJ include invasive dental procedures (tooth extraction, dental implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures). The risk may increase with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
How is ONJ diagnosed and managed in patients taking Fosamax?
ONJ is diagnosed through clinical examination and imaging, identifying necrotic bone that persists for more than eight weeks in the absence of jaw radiation. Management includes discontinuing the bisphosphonate and addressing local factors such as infection or dental procedures. The label advises discontinuation if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.